Literature DB >> 19501152

Diferuloylmethane augments the cytotoxic effects of piplartine isolated from Piper chaba.

D Jyothi1, P Vanathi, P Mangala Gowri, V Rama Subba Rao, J Madhusudana Rao, A S Sreedhar.   

Abstract

Natural compound based anticancer drug discovery is gaining interest against a wide variety of tumors. E-piplartine (trans-piplartine), a natural compound isolated from Piper chaba roots is examined against rat histiocytoma (BC-8), mouse embryonal carcinoma (PCC4), mouse macrophages (P388D1 and J774), and human neuroblastoma (IMR32) tumor cells. While Z-piplartine (cis-piplartine) failed to induce cytotoxicity (even at higher concentrations, 50 microM), E-piplartine induced a dose-dependent cytotoxicity (2-24 microM) in different tumor cells. The combinatorial treatment of piplartine with diferuloylmethane (curcumin), an anti-inflammatory and anticancer agent, significantly enhanced the piplartine induced cytotoxicity in tumor cells. Diferuloylmethane itself is not cytotoxic at 15 microM concentration; however, potentiated the piplartine induced cytotoxicity. The tumor cell killing with piplartine is preceded by G1 cell cycle arrest, and surpassed diferuloylmethane induced G2/M arrest when used in combination. In PCC4 cells, piplartine inhibited the cell cycle progression by inactivating cdk2 and destabilizing cyclin D1, whereas diferuloylmethane combination inhibited the ERK1/2 and Raf-1 signaling in addition to the inhibition of cell cycle progression. The over expression of heat shock protein 70, Hsp70 in rat histiocytic tumor cells interfered with piplartine induced cytotoxicity, hence, a cross talk between stress response and anticancer agents is presented. Our data demonstrates the biological and medicinal importance of piplartine isolated from the roots of P. chaba, and indicates that E-piplartine may be a promising candidate to use in combinatorial treatments to combat cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501152     DOI: 10.1016/j.tiv.2009.05.023

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  6 in total

1.  Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling.

Authors:  Dong Ju Son; Soo Yeon Kim; Seong Su Han; Chan Woo Kim; Sandeep Kumar; Byeoung Soo Park; Sung Eun Lee; Yeo Pyo Yun; Hanjoong Jo; Young Hyun Park
Journal:  Biochem Biophys Res Commun       Date:  2012-09-17       Impact factor: 3.575

2.  Anti-microbial principles of selected remedial plants from Southern India.

Authors:  Rao G Tirupathi; Babu K Suresh; Kumar J Ujwal; P Sujana; A Veerabhadr Raoa; A S Sreedhar
Journal:  Asian Pac J Trop Biomed       Date:  2011-08

3.  Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells.

Authors:  Cinara O D'Sousa Costa; João H Araujo Neto; Ingrid R S Baliza; Rosane B Dias; Ludmila de F Valverde; Manuela T A Vidal; Caroline B S Sales; Clarissa A G Rocha; Diogo R M Moreira; Milena B P Soares; Alzir A Batista; Daniel P Bezerra
Journal:  Oncotarget       Date:  2017-11-01

4.  An optimized molecular inclusion complex of diferuloylmethane: enhanced physical properties and biological activity.

Authors:  Qunyou Tan; Yi Li; Jianyong Wu; Hu Mei; Chunjing Zhao; Jingqing Zhang
Journal:  Int J Nanomedicine       Date:  2012-10-09

5.  17AAG Treatment Accelerates Doxorubicin Induced Cellular Senescence: Hsp90 Interferes with Enforced Senescence of Tumor Cells.

Authors:  Upasana Sarangi; Khande Rao Paithankar; Jonnala Ujwal Kumar; Vaidyanathan Subramaniam; Amere Subbarao Sreedhar
Journal:  Drug Target Insights       Date:  2012-08-06

6.  Anti-angiogenic and anti-proliferative effects of Benja-ummarit extract in rats with hepatocellular carcinoma.

Authors:  Nattpawit Kaewnoonual; Arunporn Itharat; Suriya Pongsawat; Cheng Nilbu-Nga; Vichununt Kerdput; Wisuit Pradidarcheep
Journal:  Biomed Rep       Date:  2020-01-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.